SAU · 4163.SR · SAR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 12:17 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SAR. Historical prices are not a forecast.
Al-Dawaa Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 43.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Al-Dawaa Medical Services Company’s forward annual dividend is SAR 2.52 per share, paid quarterly. The forward yield is 6.83% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Al-Dawaa Medical Services Company’s next earnings report is currently expected on Nov 4, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Al-Dawaa Medical Services Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Al-Dawaa Medical Services Company operates as a prominent pharmaceutical retail enterprise throughout the Kingdom of Saudi Arabia, conducting its business through distinct retail and wholesale divisions. The company provides a comprehensive selection of products, including pharmaceuticals, fragrances, beauty accessories, cosmetics, and other general healthcare items. Beyond its core sales operations, Al-Dawaa is actively involved in managing pharmacies, overseeing pharmaceutical warehouses, retailing medical equipment, offering land transportation for goods, managing self-storage facilities, and providing marketing services for external entities. It also serves as a pharmaceutical agent. The company connects with customers via an extensive network of 837 pharmacies, augmented by its online and wholesale distribution channels. Al-Dawaa Medical Services Company was established in 1991 and is based in Al Khobar, Saudi Arabia.
Latest available per-share figures in SAR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 02:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Mar 17, 2025 |
| SAR 1.22+37.08% vs estimate |
| SAR 1.75B+9.26% vs estimate |
| Q3 2024 | Nov 4, 2024 | SAR 0.88-9.28% vs estimate | SAR 1.63B+3.76% vs estimate |
|---|
| Q2 2024 | Aug 4, 2024 | SAR 1.13-11.02% vs estimate | SAR 1.59B+4.13% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SAR 221.50-SAR 1.60 (-0.72%)
Dr. Sulaiman Al Habib Medical Services Group Company’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
SAR 91.20+SAR 0.20 (+0.22%)
Nahdi Medical Company’s quoted price sits in the lower half of its reported 52-week range, 21.92% below the high.
SAR 55.20-SAR 0.40 (-0.72%)
Mouwasat Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
SAR 119.90-SAR 2.10 (-1.72%)
Jamjoom Pharmaceuticals Factory Company’s quoted price sits in the lower half of its reported 52-week range, 26.76% below the high.
SAR 64.95-SAR 0.65 (-0.99%)
Dallah Healthcare Company’s quoted price sits in the lower half of its reported 52-week range, 49.09% below the high.
SAR 61.20+SAR 0.25 (+0.41%)
Middle East Pharmaceutical Industries Company’s quoted price sits in the lower half of its reported 52-week range, 22.0% below the high.
SAR 20.99SAR 0.00 (0.0%)
Almujtama Alraida Medical Co.’s quoted price sits in the lower half of its reported 52-week range, 33.37% below the high.
SAR 22.50-SAR 0.34 (-1.49%)
Al-Razi Medical Co.’s quoted price sits in the lower half of its reported 52-week range, 42.84% below the high.
